Prioritization of Potential Drugs Through Pathway-Based Drug Repurposing and Network Proximity Analysis
Otero Carrasco, B.; Prieto Santamaria, L.; Rodriguez Gonzalez, A.
Show abstract
Drug repurposing is an effective strategy to identify novel therapeutic options by leveraging existing drugs with known mechanisms of action and safety profiles. This work introduces a pathway-based drug repurposing approach that combines protein-protein interaction (PPI) networks and transcriptomic data to prioritize candidate drugs. The underlying assumption is that if disease 1 and disease 2 are both associated with the same biological pathway, then drugs known to be effective for disease 2 may be potential treatments for disease 1. To explore these relationships, disease-pathway-drug triplets are constructed. Genes shared between disease 1 and the associated pathway are identified, and their proximity is calculated within the PPI network using a Z-score based on random permutations. Candidate drugs for disease 2 are then analyzed using the Connectivity Map data, assessing whether their up- or down-regulated gene signatures are enriched for the genes contributing to the proximity between disease 1 and the pathway. This integration enables the ranking of candidate drugs based on their potential biological impact on disease 1. Finally, top-ranked drug-disease associations are evaluated through manual curation of the scientific literature to assess existing evidence supporting the proposed repurposing hypothesis.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Network-based estimation of therapeutic efficacy and adverse reaction potential for prioritisation of anti-cancer drug combinations 96%
- Drug repositoning or target repositioning: a structural perspective of drug-target-indication relationship for available repurposed drugs. 95%
- DrugForm-DTA: Towards real-world drug-target binding Affinity Model 94%
Similar papers in this journal
- DReAmocracy: A Method to Capitalize on Prior Drug Discovery Efforts to Highlight Candidate Drugs for Repurposing 96%
- Multiscale Analysis And Validation Of Effective Drug Combinations Targeting Driver Kras Mutations In Non-Small Cell Lung Cancer 95%
- Multi-run Concrete Autoencoder to Identify Prognostic lncRNAs for 12 Cancers 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.